Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia

Authors


Richard Williams, Director Schizophrenia Service, Eric Martin Pavilion, 2334 Trent Street, Victoria, BC, Canada V8R 4Z3.
E-mail: richard.williams@viha.ca

Abstract

Objective:  To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment.

Method:  A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years.

Results:  Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized.

Conclusion:  There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period.

Ancillary